US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
ANI Pharmaceuticals, Inc. - Common Stock
(NQ:
ANIP
)
71.17
-1.43 (-1.97%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ANI Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
October 06, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...
Via
StockStory
1 Small-Cap Stock for Long-Term Investors and 2 We Ignore
October 01, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
3 Profitable Stocks Worth Investigating
September 29, 2026
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia...
Via
StockStory
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
September 23, 2026
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...
Via
StockStory
ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat
↗
August 07, 2026
Via
Chartmill
2 Cash-Producing Stocks to Target This Week and 1 We Avoid
September 18, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
2 Value Stocks on Our Watchlist and 1 We Find Risky
September 01, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via
StockStory
2 Reasons to Like ANIP (and 1 Not So Much)
August 27, 2026
ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock als...
Via
StockStory
Topics
Supply Chain
1 Russell 2000 Stock to Target This Week and 2 We Brush Off
August 24, 2026
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Via
StockStory
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
↗
August 14, 2026
Rare disease revenue surged 43.5% as Cortrophin Gel sales accelerated across key specialties.
Via
The Motley Fool
Topics
Earnings
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call
August 14, 2026
ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively t...
Via
StockStory
Topics
Earnings
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks
August 12, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration
August 08, 2026
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 25.9...
Via
StockStory
ANI Pharmaceuticals Q2 Earnings Call Highlights
↗
August 07, 2026
ANI Pharmaceuticals (NASDAQ:ANIP) reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the...
Via
MarketBeat
Topics
Earnings
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance
August 07, 2026
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.9% ...
Via
StockStory
Topics
Earnings
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
August 06, 2026
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings tomorrow before the bell. Here’s what to look for. ANI Pharmace...
Via
StockStory
Topics
Artificial Intelligence
1 Healthcare Stock Worth Your Attention and 2 We Question
July 30, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via
StockStory
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
July 27, 2026
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
July 26, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
July 24, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Via
StockStory
2 Reasons to Watch ANIP and 1 to Stay Cautious
July 24, 2026
Since January 2026, ANI Pharmaceuticals has been in a holding pattern, posting a small loss of 3.5% while floating around $78.49. The stock also fell short o...
Via
StockStory
2 Small-Cap Stocks Worth Investigating and 1 We Brush Off
July 21, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
↗
July 12, 2026
Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares.
Via
The Motley Fool
Topics
Economy
Regulatory Compliance
2 Value Stocks for Long-Term Investors and 1 We Avoid
July 10, 2026
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Via
StockStory
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
↗
July 09, 2026
This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
July 06, 2026
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 of Wall Street’s Favorite Stocks to Target This Week
July 06, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
June 09, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Ani (ANIP) Q1 2026 Earnings Call Transcript
↗
June 01, 2026
Ani (ANIP) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
2 Growth Stocks with Explosive Upside and 1 We Avoid
May 29, 2026
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
